Jenburkt Pharmaceuticals Ltd Fair Value
JENBURKTPHARMACEUTICALSLTD · Healthcare · Current price
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹596 | 19% ROE fading to 12% over ~10 yrs, on ₹446 book |
| Relative P/E | ₹2,427 | EPS × 38.2 peer-median P/E |
| Graham floor | ₹799 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Jenburkt Pharmaceuticals Ltd undervalued?
We couldn't compute a reliable fair value for Jenburkt Pharmaceuticals Ltd from the available data. This usually means key inputs (earnings, book value, or cash flow) are missing or inconsistent.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹596), Relative P/E (₹2,427), Graham floor (₹799). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹596 (bear) to ₹1,143 (base) to ₹2,427 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Jenburkt Pharmaceuticals Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.